CD69 serves as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma

Kaihua Tang, Xiaoting Li, Jianwen Mo, Yixuan Chen, Chengyu Huang, Ting Li, Tianjian Luo, Zhijian Zhong, Yongqiang Jiang, Dengfeng Yang, Weiliang MoScientific 2023 · DOI

TL;DR

This study identifies CD69 as a promising diagnostic and prognostic biomarker for hepatocellular carcinoma (HCC). By analyzing multiple public datasets, researchers found that CD69 expression is linked to apoptosis and immune cell infiltration, and its downregulation is associated with poorer patient outcomes, suggesting its potential as a therapeutic target.

What Problem Does This Paper Address?

Hepatocellular carcinoma (HCC) remains a significant global health challenge with high mortality rates and a tendency for recurrence even after treatment. Current therapeutic options for advanced HCC are limited, and there's a critical need for better diagnostic tools and more effective treatment strategies. Specifically, understanding the molecular mechanisms underlying HCC progression and identifying reliable biomarkers for prognosis are crucial for improving patient survival. This paper aims to address this by investigating the role of cell death pathways and immune microenvironment in HCC and identifying key genes that can serve as prognostic indicators.

Methods

The researchers employed a multi-omics approach, integrating gene expression data from multiple public datasets. Key methods included:

  • Differential Gene Expression Analysis: Identifying genes that are significantly up- or down-regulated in HCC tumors compared to normal liver tissue across four independent datasets.
  • Gene Set Enrichment Analysis (GSEA) and Gene Set Variation Analysis (GSVA): Evaluating the enrichment of specific biological pathways, particularly those related to cell death (apoptosis, necroptosis, pyroptosis, etc.), and assessing their activity levels across samples.
  • Least Absolute Shrinkage and Selection Operator (LASSO) Regression: A statistical method used to select a subset of relevant genes from a larger set, particularly useful for identifying genes with prognostic value while preventing overfitting. This was applied to genes involved in cell death pathways that significantly impacted overall survival.
  • Immune Cell Infiltration Analysis: Using tools like CIBERSORT and ssGSEA to quantify the abundance of various immune cell types within HCC tumors and assess their correlation with gene expression.
  • Kaplan-Meier (K-M) Survival Analysis: A statistical method to estimate and compare survival distributions between different groups of patients (e.g., high vs. low gene expression).
  • Receiver Operating Characteristic (ROC) Curve Analysis: Used to evaluate the diagnostic performance of candidate genes by assessing their ability to discriminate between HCC patients and controls.
  • Nomogram Construction: A graphical tool used to predict the probability of an event (in this case, survival) based on multiple predictor variables.

Datasets

The study utilized publicly available gene expression datasets from the following sources:

  • The Cancer Genome Atlas (TCGA): Provided gene expression profiles for 369 tumor tissues and 50 matched control liver tissues.
  • Gene Expression Omnibus (GEO):
    • GSE25097: Included 268 tumor and 249 control liver tissues.
  • GSE36376: Included 240 tumor and 193 non-tumor liver tissues.
  • GSE76427: Included 115 tumor and 52 adjacent non-tumor liver tissues.

Key Insights and Ideas

  • Apoptosis is Suppressed in HCC: The study found significant evidence that apoptosis, a crucial programmed cell death pathway, is suppressed in HCC. This suppression is a key finding that links cell death mechanisms to cancer progression.
  • CD69 as a Dual Player: CD69 emerged as a significant gene, showing a dual role. It's implicated in cell death pathways (specifically apoptosis) and also strongly correlates with immune cell infiltration, particularly T cells. This suggests CD69 acts as a bridge between cellular processes and the immune response in HCC.
  • CD69's Protective Role: Unlike some other identified candidate genes, CD69 appears to have a protective effect. Higher expression of CD69 was associated with better overall survival in HCC patients, suggesting it might help combat tumor growth or enhance anti-tumor immunity.
  • Immune Microenvironment Alterations: The study detailed significant changes in immune cell infiltration in HCC, with some cell types being over-represented and others under-represented. This highlights the complex interplay between the tumor and its surrounding immune environment.
  • Candidate Gene Panel for Prognosis: Beyond CD69, the LASSO regression identified a panel of genes (CDC25B, MGMT, TOP2A, and TXNIP) that, along with CD69, can be used to predict patient prognosis.

Key Results

  • 4088 Common Differentially Expressed Genes (DEGs): After analyzing four datasets, 4088 DEGs were identified with consistent expression direction across all of them, primarily enriched in immunoinflammation and cell cycle pathways.
  • Apoptosis Suppression Confirmed: GSEA and GSVA analyses consistently showed that apoptosis was significantly suppressed in HCC.
  • Five Candidate Genes Identified: LASSO regression identified CD69, CDC25B, MGMT, TOP2A, and TXNIP as candidate genes impacting patient prognosis.
  • CD69 Significantly Impacts Survival: CD69 was found to significantly influence overall survival in both the TCGA and GSE76427 datasets, with higher expression correlating with better outcomes.
  • Diagnostic Potential: ROC curve analyses indicated that these candidate genes, especially CD69, possess good sensitivity and specificity for predicting HCC. For instance, CD69 achieved an AUC of 0.69 in GSE76427 and 0.81 in TCGA.
  • Immune Correlation: CD69 showed a strong positive correlation with T cells and CD3E, suggesting its role in modulating the immune response within the tumor microenvironment.

Limitations and Future Work

The authors acknowledge several limitations:

  • Reliance on Public Data: The study is based on publicly available datasets, and clinical validation with a larger cohort, especially considering factors like hepatitis B/C infection, is needed.
  • Mechanistic Understanding: While associations are found, the precise molecular mechanisms by which CD69, as an apoptosis-related gene, influences HCC pathology remain to be fully elucidated.
  • Lack of Experimental Validation: The study relied on bioinformatics analysis. Further experimental validation, including functional experiments and molecular mechanism studies, is required to confirm these findings and establish causal relationships.

Future work should focus on:

  • Experimental Validation: Conducting in vitro and in vivo experiments to confirm the roles of CD69 and other candidate genes in HCC pathogenesis and prognosis.
  • Clinical Correlation: Validating these findings in larger, diverse clinical cohorts to assess their diagnostic and prognostic utility in real-world settings.
  • Therapeutic Development: Exploring how targeting CD69 or other identified genes could lead to new therapeutic strategies for HCC, potentially by modulating apoptosis or enhancing anti-tumor immunity.

Summary updated

Abstract

The prevalence and mortality of hepatocellular carcinoma (HCC) are still increasing. This study aimed to identify potential therapeutic targets related to patient prognosis. Data were downloaded from TCGA, GSE25097, GSE36376, and GSE76427 datasets. Differential analysis and enrichment analysis were performed in HCC. Cell deaths were evaluated, and least absolute shrinkage and selection operator regression (LASSO) regression was analyzed to screen candidate genes. Additionally, immune cell infiltration in HCC was assessed. We identified 4088 common DEGs with the same direction of differential expression in all four datasets, they were mainly enriched in immunoinflammation and cell cycle pathways. Apoptosis was significantly suppressed in HCC in GSEA and GSVA. After LASSO regression analysis, we screened CD69, CDC25B, MGMT, TOP2A, and TXNIP as candidate genes. Among them, CD69 significantly influenced the overall survival of HCC patients in both TCGA and GSE76427. CD69 may be a protective factor for outcome of HCC patients. In addition, CD69 was positive correlation with T cells and CD3E. CD69, CDC25B, MGMT, TOP2A, and TXNIP were potential diagnostic and prognostic target for HCC, especially CD69.
BibTeX
@inproceedings{tang2023cd,
  author = {Kaihua Tang and Xiaoting Li and Jianwen Mo and Yixuan Chen and Chengyu Huang and Ting Li and Tianjian Luo and Zhijian Zhong and Yongqiang Jiang and Dengfeng Yang and Weiliang Mo},
  title = {{CD69 serves as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma}},
  booktitle = {Scientific},
  year = {2023},
  doi = {10.1038/s41598-023-34261-1},
}
Figure